Find similiar products:
The text only version may be available in large print, Braille or audio CD.
For further information call emc accessibility on
0800 198 5000.
The product code(s) for this leaflet is: PL 16973/0044.
Wynzora 50 micrograms/g + 0.5 mg/g cream
Wynzora 50 micrograms/g + 0.5 mg/g cream
calcipotriol/betamethasone
1. What Wynzora is and what it is used for
2. What you need to know before you use Wynzora
3. How to use Wynzora
4. Possible side effects
5. How to store Wynzora
6. Contents of the pack and other information
Wynzora is used on the skin to treat mild to moderate psoriasis vulgaris, including scalp psoriasis in adults. Psoriasis is caused by your skin cells being produced too quickly. This causes redness, scaling and thickness of your skin.
Wynzora contains calcipotriol and betamethasone. Calcipotriol helps to bring the rate of skin cell growth back to normal and betamethasone acts to reduce inflammation.
As Wynzora contains a strong steroid, do NOT use it on skin affected by:
Talk to your doctor, pharmacist or nurse before using Wynzora if:
Talk to your doctor, pharmacist or nurse during treatment if:
Special precautions
Do not smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
Wynzora is not recommended for the use in children below the age of 18 years.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Pregnancy
Use of Wynzora during pregnancy should only take place as directed by a doctor.
Breast-feeding
Use of Wynzora during breast-feeding should only take place as directed by a doctor.
Do not apply Wynzora to the breast if you are breast-feeding.
This medicine has no or negligble effect on your ability to drive or use machines.
Butylhydroxyanisole (E320) may cause local skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. Macrogolglycerol hydroxystearate may cause local skin reactions.
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Wynzora is for cutaneous use (on the skin).
When used on the body
When used on the scalp
Duration of treatment
If you use other calcipotriol containing medicines, the total amount of calcipotriol medicines must not exceed 15 grams per day, and the area treated should not exceed 30% of the total body surface.
Most patients see obvious results after 1 week, even if the psoriasis is not yet cleared at that point.
Contact your doctor if you have used more than 15 grams in one day.
Excessive use of Wynzora may also cause a problem with calcium in your blood, which usually normalises when discontinuing treatment. Your doctor may need to carry out blood tests to check that using too much cream has not caused a problem with calcium in your blood.
Excessive prolonged use can also cause your adrenal glands to stop working properly (the adrenal glands are found near the kidneys and produce hormones).
Do not take a double dose to make up for a forgotten dose.
The use of Wynzora should be stopped as indicated by your doctor. It may be necessary for you to stop this medicine gradually, especially if you have used it for a long time.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Uncommon (may affect up to 1 in 100 people):
Frequency not known (frequency cannot be estimated from the available data):
Wynzora contains betamethasone and calcipotriol. You may therefore experience the following side effects. These side effects are more likely to happen if Wynzora is used for a long time, if used under dressings or in skin folds (e.g. groin, armpits or under breasts), or if used on large skin areas:
If you experience any of the above side effects you should contact your doctor immediately.
Less serious side effects known to be caused by calcipotriol or betamethasone include the following:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:
Ireland
United Kingdom (Northern Ireland)
The Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or tube after EXP. The expiry date refers to the last day of that month.
Do not store above 25°C.
Do not freeze.
Discard the tube with any remaining cream 6 months after first opening.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Wynzora is a white cream filled in aluminium tubes coated with epoxyphenol and with polyethylene screw cap.
Pack size: 1 tube of 60 g or multipack 120g (2 cartons each containing 1 tube of 60g ).
Not all pack sizes may be marketed.
This medicinal product is authorised in the Member States of the EEA under the following names:
DK Wynzora
AT Winxory 50 Mikrogramm/g + 0,5 mg/g Creme
CZ Wynzora
DE Wynzora 50 Mikrogramm/g + 0,5 mg/g Creme
ES Wynzora 50 microgramos / g + 0.5 mg/g crema
FI Wynzora 50/500 mikrog/g emulsiovoide
FR Wynzora 50 micrograms/0,5 mg per g crème
IE Wynzora 50 micrograms/g + 0.5 mg/g cream
IT Wynzora
NL Wynzora 50 microgrm/g + 0.5 mg/g crème
NO Wynzora
PL Wynzora
PT Wynzora, 50 microgramas/g + 0.5 mg/g crème
SE Wynzora
UK(NI) Wynzora, 50 micrograms/g + 0.5 mg/g cream
This leaflet was last revised in February 2022.